Latest Clinical Trials News

Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.

Visioneering Technologies reports promising interim results from its PROTECT trial, showing significant control of myopia progression in children using NaturalVue® Multifocal lenses.

Dimerix has reached a key milestone by enrolling the first paediatric patient aged 12-17 in its ACTION3 Phase 3 trial for DMX-200, advancing its potential treatment for childhood FSGS kidney disease.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.